Editor - Michael Robert McDevitt | Zuckerman Research Laboratory | 9171

OMICS Journal of Radiology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Michael Robert McDevitt

Michael Robert McDevitt
Michael Robert McDevitt
Memorial Sloan-Kettering Cancer Center
Zuckerman Research Laboratory
Tel. 646-888-2192
Fax 646-422-0640


Michael R. McDevitt is a research scientist in the Departments of Medicine and Radiology at Memorial Sloan-Kettering Cancer Center in New York. He specializes in the development and clinical translation of targeted radiolabeled drug constructs to treat cancer and other diseases. Radioconstructs are drugs that combine antibodies and radionuclides for therapeutic and imaging applications in the treatment of cancer. His research involves the investigation of new chemistry, radiochemistry, biological activity, pharmacokinetics, safety, stability and the translation of new constructs into the clinic. He has also been investigating novel nanomaterial-based constructs and incorporating these materials into drug design strategies. After receiving his PhD degree from Case Western Reserve University, in 1985, Dr. McDevitt worked in biotechnology and joined MSKCC in 1995. In 2004, he received a master’s degree in engineering from The City University of New York. He is also a member of MSKCC’s Brain Tumor Center and Nanotechnology Center.

Research Interest

Michael R. McDevitt  Develop radionuclide-labeled antibody constructs that target antigens expressed on tumor and tumor vasculature as therapeutic and diagnostic agents for the treatment of cancer. Investigate the pharmacokinetic profile of carbon nanotube scaffolds as unique delivery platforms for tumor and tumor vascular radiotherapy and imaging applications. Investigate the chemistry and biology of novel functionalized nanomaterials as targeting vectors to improve the specific cellular delivery of siRNA. Translation of radiolabeled alpha-, beta-and positron-emitting drug constructs into the clinic.Develop and facilitate the routine clinical use of radionuclide generator systems.